Comprehensive Drug Pricing Reform & Biosimilar Acceleration Act

Bill Bounty Poster #3: Comprehensive Drug Pricing Reform & Biosimilar Acceleration Act

Legislative Priority Classification

Urgency Level: HIGH Feasibility Score: 6/10 Coalition Potential: Partisan divide with crossover potential

Policy Problem Statement

IRA 2022 negotiation provisions cover only 10 drugs initially; insulin cap doesn’t address root pricing dysfunction. Biosimilar adoption lags Europe by 40%. Pharmacy Benefit Manager (PBM) practices inflate costs while reducing pharmacy margins. Patients face $1,400 average annual out-of-pocket costs for chronic disease management.

Core Legislative Components

Tier 1: Negotiation Expansion

• Accelerate Medicare negotiation timeline: 30 drugs by 2027 (vs. current 20 by 2029)
• Include commercial market in reference pricing framework (voluntary state opt-in)
• Establish independent Drug Pricing Review Board (modeled on IPAB with legislative override protection removed)

Tier 2: Biosimilar Ecosystem Development

• FDA purple book accessibility grants for provider EHR integration
• Automatic substitution for pharmacies unless prescriber documents medical necessity
• Shield laws protecting pharmacists who substitute biosimilars from liability
• Marketing exclusivity reduction from 12 to 8 years for new biologics

Tier 3: PBM Structural Reform

• Mandatory pass-through pricing for manufacturer rebates (100% to plan sponsors/patients)
• Ban spread pricing in Medicaid managed care
• Prohibit retroactive DIR fees; require point-of-sale transparency
• Fiduciary duty standard for formulary placement decisions

Tier 4: Manufacturing Security

• Domestic production incentives for 50 critical drugs (tax credits + expedited FDA review)
• Strategic National Stockpile modernization focused on biosimilar redundancy
• API (Active Pharmaceutical Ingredient) supply chain mapping with China-alternative sourcing requirements

Galveston Framework Integration

Advances Sustainability Principle: Ensures clinic and community health center formulary affordability. Enables MSA-level purchasing cooperatives to negotiate favorable pricing through transparent PBM structures.

Implementation Mechanics

• CMS/FDA joint rulemaking authority for negotiation and biosimilar frameworks
• FTC enforcement for PBM practices under enhanced UDAP (Unfair/Deceptive Acts or Practices) authority
• 3-year implementation with sunset review requiring Congressional reauthorization

Estimated Impact Metrics

• Patient Savings: $89B over 10 years (CBO preliminary scoring)
• Medicare Part D Solvency: Extends trust fund viability by 4.3 years
• Biosimilar Market Share: Projected increase from 38% to 71% of eligible prescriptions
• Drug Shortages: 30% reduction through domestic manufacturing incentives

Legislative Champion Profile

Ideal Sponsors: Finance/HELP Committee progressives + fiscal conservative concerned with deficit reduction Opposition Analysis: PhRMA will mobilize against negotiation expansion; PBM middlemen will fund astroturf campaigns; biosimilar provisions may gain industry neutrality